Each retail package of Sucanon contains 60 tablets and is the equivalent of a one-month patient supply.
Pre-clinical and clinical studies of Sucanon showed that Sucanon and other insulin sensitizer’s lower a patient’s blood sugar by increasing the muscle, fat and liver’s sensitivity to the body’s own naturally produced insulin.
Fero Industries director and the company’s Mexican subsidiary Pharmaroth president Luis Lopez said maintaining absolute quality and formulation control while expanding Sucanon manufacturing and packaging capabilities will continue to be an essential component of their global growth strategy.
Sucanon is approved by regulatory authorities in Mexico and is distributed there under an exclusive agreement with Merck SA de CV, the Mexico and Latin America sales and marketing organization of Germany-based Merck KGaA.